Fred Hutchinson Cancer Center is a world leader in Myelodysplastic Syndrome (MDS) research. Our experts are developing innovative ways to detect and diagnose MDS, unraveling how MDS progresses to ...
The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes. A new report explains why patients with myelodysplastic syndromes (MDS) become ...
The phase 3 trial for high-risk MDS with RARA overexpression did not achieve its primary endpoint of CR rate. Tamibarotene-Vidaza treatment showed a 23.8% CR rate, not significantly different from the ...
Myelodysplastic syndromes (MDS) are a group of disorders in which a person’s bone marrow does not produce enough functioning blood cells. MDS is a type of cancer that damages some of the blood-forming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results